ITCI241220C70000
- 14.35
- -0.45-3.04%
Intra-Cellular Therapies Newsroom
S&P 500 Futures Drop In Premarket Trading; Intra-Cellular Therapies, Avantor Lag
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Insider Sale: Chairman and CEO of $ITCI (ITCI) Sells 1,534 Shares
Intra-Cellular Therapies(ITCI.US) Officer Sells US$8.72 Million in Common Stock
Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.34 Million in Common Stocks
Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.37 Million in Common Stocks
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder
Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020
Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock
Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 3.7 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael intends to sell 41,583 shares of its common stock on Nov 12, with a total market value of approximately $3.